We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
FORM 3
|
Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person * Curran Terrie |
2. Date of Event Requiring Statement (MM/DD/YYYY)
|
3. Issuer Name and Ticker or Trading Symbol CELGENE CORP /DE/ [CELG] |
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below) See remarks / |
|
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned |
|||
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock | 4710 | D | |
Common Stock | 599 | I | 401(k) Plan |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (1) (2) | 5/1/2023 | Common Stock | 6572 | $58.33 | D | |
Stock Option (right to buy) | (1) (2) | 5/1/2023 | Common Stock | 3428 | $58.33 | D | |
Stock Option (right to buy) | (1) (3) | 12/2/2023 | Common Stock | 3750 | $81.56 | D | |
Stock Option (right to buy) | (1) (4) | 7/28/2024 | Common Stock | 6359 | $87.64 | D | |
Stock Option (right to buy) | (1) (5) | 7/28/2024 | Common Stock | 1141 | $87.64 | D | |
Stock Option (right to buy) | (1) (6) | 10/27/2024 | Common Stock | 5000 | $103.10 | D | |
Stock Option (right to buy) | (1) (7) | 12/19/2024 | Common Stock | 7050 | $117.18 | D | |
Stock Option (right to buy) | (1) (8) | 2/2/2025 | Common Stock | 4157 | $118.57 | D | |
Stock Option (right to buy) | (1) (9) | 2/2/2025 | Common Stock | 843 | $118.57 | D | |
Stock Option (right to buy) | (1) (10) | 5/4/2025 | Common Stock | 2500 | $109.90 | D | |
Stock Option (right to buy) | (1) (11) | 7/27/2025 | Common Stock | 2500 | $132.56 | D | |
Stock Option (right to buy) | (1) (12) | 11/9/2025 | Common Stock | 2500 | $114.08 | D | |
Stock Option (right to buy) | (1) (13) | 2/1/2026 | Common Stock | 1875 | $100.80 | D | |
Stock Option (right to buy) | (1) (14) | 2/1/2026 | Common Stock | 625 | $100.80 | D | |
Stock Option (right to buy) | (1) (15) | 5/2/2026 | Common Stock | 2773 | $104.97 | D | |
Stock Option (right to buy) | (1) (16) | 5/2/2026 | Common Stock | 352 | $104.97 | D | |
Stock Option (right to buy) | (1) (17) | 8/1/2026 | Common Stock | 3125 | $114.69 | D | |
Stock Option (right to buy) | (1) (18) | 10/31/2026 | Common Stock | 6562 | $102.18 | D | |
Stock Option (right to buy) | (1) (19) | 1/30/2027 | Common Stock | 5680 | $113.18 | D | |
Stock Option (right to buy) | (1) (20) | 1/30/2027 | Common Stock | 883 | $113.18 | D | |
Stock Option (right to buy) | (1) (21) | 5/1/2027 | Common Stock | 6776 | $124.06 | D | |
Restricted Stock Unit | (22) | (22) | Common Stock | 1500 | (23) (24) | D | |
Restricted Stock Unit | (25) | (25) | Common Stock | 1765 | (23) (24) | D | |
Restricted Stock Unit | (26) | (26) | Common Stock | 2500 | (23) (24) | D | |
Restricted Stock Unit | (27) | (27) | Common Stock | 2500 | (23) (24) | D | |
Restricted Stock Unit | (28) | (28) | Common Stock | 1563 | (23) (24) | D | |
Restricted Stock Unit | (29) | (29) | Common Stock | 3281 | (23) (24) | D | |
Restricted Stock Unit | (30) | (30) | Common Stock | 3426 | (23) (24) | D |
Remarks:
President Inflammation & Immunology |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Curran Terrie
86 MORRIS AVENUE SUMMIT, NJ 07901 |
|
|
See remarks |
|
Signatures
|
||
/s/ Terrie J. Curran | 6/23/2017 | |
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions